Movement disorders and depression due to flunarizine and cinnarizine.
Identifieur interne : 004F76 ( PubMed/Curation ); précédent : 004F75; suivant : 004F77Movement disorders and depression due to flunarizine and cinnarizine.
Auteurs : F E Micheli [Argentine] ; M M Pardal ; R. Giannaula ; M. Gatto ; I. Parera ; G. Paradiso ; M. Torres ; R. Pikielny ; J. PardalSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1989.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Basal Ganglia Diseases (chemically induced), Cinnarizine (adverse effects), Cinnarizine (therapeutic use), Depression (chemically induced), Dyskinesia, Drug-Induced (etiology), Dystonia (chemically induced), Female, Flunarizine (adverse effects), Flunarizine (therapeutic use), Humans, Male, Middle Aged, Parkinson Disease, Secondary (chemically induced), Tremor (chemically induced).
- MESH :
- chemical , adverse effects : Cinnarizine, Flunarizine.
- chemically induced : Basal Ganglia Diseases, Depression, Dystonia, Parkinson Disease, Secondary, Tremor.
- etiology : Dyskinesia, Drug-Induced.
- chemical , therapeutic use : Cinnarizine, Flunarizine.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged.
Abstract
Over the last few years, cases of movement disorders induced by flunarizine and cinnarizine have been increasingly reported. We describe a series of 101 patients, whose ages ranged from 37 to 84 years (mean 69.1), developing abnormal movements frequently associated with depression, secondary to treatment with either or both drugs. Symptoms closely resembled those induced by neuroleptic drugs and remitted on drug discontinuance in all but five cases after 5-22 months' follow-up. Whether or not such undesirable side effects are attributable to calcium antagonism and/or dopamine receptor blockade, long-term treatment with flunarizine or cinnarizine should be discouraged, particularly in the elderly.
DOI: 10.1002/mds.870040205
PubMed: 2733706
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004F76
Links to Exploration step
pubmed:2733706Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Movement disorders and depression due to flunarizine and cinnarizine.</title><author><name sortKey="Micheli, F E" sort="Micheli, F E" uniqKey="Micheli F" first="F E" last="Micheli">F E Micheli</name><affiliation wicri:level="1"><nlm:affiliation>Neurology Department, Hospital de Clínicas José de San Martín, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Neurology Department, Hospital de Clínicas José de San Martín, Buenos Aires</wicri:regionArea></affiliation></author><author><name sortKey="Pardal, M M" sort="Pardal, M M" uniqKey="Pardal M" first="M M" last="Pardal">M M Pardal</name></author><author><name sortKey="Giannaula, R" sort="Giannaula, R" uniqKey="Giannaula R" first="R" last="Giannaula">R. Giannaula</name></author><author><name sortKey="Gatto, M" sort="Gatto, M" uniqKey="Gatto M" first="M" last="Gatto">M. Gatto</name></author><author><name sortKey="Parera, I" sort="Parera, I" uniqKey="Parera I" first="I" last="Parera">I. Parera</name></author><author><name sortKey="Paradiso, G" sort="Paradiso, G" uniqKey="Paradiso G" first="G" last="Paradiso">G. Paradiso</name></author><author><name sortKey="Torres, M" sort="Torres, M" uniqKey="Torres M" first="M" last="Torres">M. Torres</name></author><author><name sortKey="Pikielny, R" sort="Pikielny, R" uniqKey="Pikielny R" first="R" last="Pikielny">R. Pikielny</name></author><author><name sortKey="Pardal, J" sort="Pardal, J" uniqKey="Pardal J" first="J" last="Pardal">J. Pardal</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1989">1989</date><idno type="RBID">pubmed:2733706</idno><idno type="pmid">2733706</idno><idno type="doi">10.1002/mds.870040205</idno><idno type="wicri:Area/PubMed/Corpus">004F76</idno><idno type="wicri:Area/PubMed/Curation">004F76</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Movement disorders and depression due to flunarizine and cinnarizine.</title><author><name sortKey="Micheli, F E" sort="Micheli, F E" uniqKey="Micheli F" first="F E" last="Micheli">F E Micheli</name><affiliation wicri:level="1"><nlm:affiliation>Neurology Department, Hospital de Clínicas José de San Martín, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Neurology Department, Hospital de Clínicas José de San Martín, Buenos Aires</wicri:regionArea></affiliation></author><author><name sortKey="Pardal, M M" sort="Pardal, M M" uniqKey="Pardal M" first="M M" last="Pardal">M M Pardal</name></author><author><name sortKey="Giannaula, R" sort="Giannaula, R" uniqKey="Giannaula R" first="R" last="Giannaula">R. Giannaula</name></author><author><name sortKey="Gatto, M" sort="Gatto, M" uniqKey="Gatto M" first="M" last="Gatto">M. Gatto</name></author><author><name sortKey="Parera, I" sort="Parera, I" uniqKey="Parera I" first="I" last="Parera">I. Parera</name></author><author><name sortKey="Paradiso, G" sort="Paradiso, G" uniqKey="Paradiso G" first="G" last="Paradiso">G. Paradiso</name></author><author><name sortKey="Torres, M" sort="Torres, M" uniqKey="Torres M" first="M" last="Torres">M. Torres</name></author><author><name sortKey="Pikielny, R" sort="Pikielny, R" uniqKey="Pikielny R" first="R" last="Pikielny">R. Pikielny</name></author><author><name sortKey="Pardal, J" sort="Pardal, J" uniqKey="Pardal J" first="J" last="Pardal">J. Pardal</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1989" type="published">1989</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Basal Ganglia Diseases (chemically induced)</term><term>Cinnarizine (adverse effects)</term><term>Cinnarizine (therapeutic use)</term><term>Depression (chemically induced)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Dystonia (chemically induced)</term><term>Female</term><term>Flunarizine (adverse effects)</term><term>Flunarizine (therapeutic use)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Tremor (chemically induced)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Cinnarizine</term><term>Flunarizine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Basal Ganglia Diseases</term><term>Depression</term><term>Dystonia</term><term>Parkinson Disease, Secondary</term><term>Tremor</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cinnarizine</term><term>Flunarizine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Over the last few years, cases of movement disorders induced by flunarizine and cinnarizine have been increasingly reported. We describe a series of 101 patients, whose ages ranged from 37 to 84 years (mean 69.1), developing abnormal movements frequently associated with depression, secondary to treatment with either or both drugs. Symptoms closely resembled those induced by neuroleptic drugs and remitted on drug discontinuance in all but five cases after 5-22 months' follow-up. Whether or not such undesirable side effects are attributable to calcium antagonism and/or dopamine receptor blockade, long-term treatment with flunarizine or cinnarizine should be discouraged, particularly in the elderly.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">2733706</PMID><DateCreated><Year>1989</Year><Month>07</Month><Day>17</Day></DateCreated><DateCompleted><Year>1989</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>1989</Year></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Movement disorders and depression due to flunarizine and cinnarizine.</ArticleTitle><Pagination><MedlinePgn>139-46</MedlinePgn></Pagination><Abstract><AbstractText>Over the last few years, cases of movement disorders induced by flunarizine and cinnarizine have been increasingly reported. We describe a series of 101 patients, whose ages ranged from 37 to 84 years (mean 69.1), developing abnormal movements frequently associated with depression, secondary to treatment with either or both drugs. Symptoms closely resembled those induced by neuroleptic drugs and remitted on drug discontinuance in all but five cases after 5-22 months' follow-up. Whether or not such undesirable side effects are attributable to calcium antagonism and/or dopamine receptor blockade, long-term treatment with flunarizine or cinnarizine should be discouraged, particularly in the elderly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Micheli</LastName><ForeName>F E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Neurology Department, Hospital de Clínicas José de San Martín, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardal</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Giannaula</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Gatto</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Parera</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Paradiso</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pikielny</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pardal</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3DI2E1X18L</RegistryNumber><NameOfSubstance UI="D002936">Cinnarizine</NameOfSubstance></Chemical><Chemical><RegistryNumber>R7PLA2DM0J</RegistryNumber><NameOfSubstance UI="D005444">Flunarizine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001480">Basal Ganglia Diseases</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002936">Cinnarizine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004421">Dystonia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005444">Flunarizine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010302">Parkinson Disease, Secondary</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014202">Tremor</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2733706</ArticleId><ArticleId IdType="doi">10.1002/mds.870040205</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F76 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004F76 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:2733706
|texte= Movement disorders and depression due to flunarizine and cinnarizine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:2733706" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |